INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 145 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.94 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $7,584 | +144.6% | 409,183 | +45.8% | 0.03% | +146.2% |
Q2 2023 | $3,100 | -43.6% | 280,561 | -31.5% | 0.01% | -45.8% |
Q1 2023 | $5,497 | +13.5% | 409,593 | +4.5% | 0.02% | 0.0% |
Q4 2022 | $4,843 | -99.7% | 391,853 | +290.2% | 0.02% | +200.0% |
Q3 2022 | $1,399,000 | +1065.8% | 100,436 | +1054.0% | 0.01% | +700.0% |
Q2 2022 | $120,000 | -93.3% | 8,703 | -92.1% | 0.00% | -85.7% |
Q1 2022 | $1,785,000 | -13.1% | 109,813 | -13.0% | 0.01% | -12.5% |
Q4 2021 | $2,055,000 | +71.1% | 126,232 | +109.9% | 0.01% | +60.0% |
Q2 2021 | $1,201,000 | +1868.9% | 60,136 | +2320.9% | 0.01% | – |
Q4 2020 | $61,000 | – | 2,484 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |